Irdeto partners with Prognoix to secure pioneering solution for stigmatized disorders

Irdeto’s Connected Health portfolio will ensure a product design that guarantees patient safety, system availability and protects private health data

AMSTERDAM – January 10, 2023 – Irdeto, the world leader in digital platform cybersecurity, today is proud to announce that it has partnered with Prognoix, a deep-tech company behind evidence-based digital medicine for stigmatized medical conditions. Irdeto’s expertise in device security and Connected Health will support Prognoix in developing a successful security strategy through a multi-dimensional approach, covering all aspects of a Secure Software Development Lifecycle.

Prognoix’s mission is to bridge the gap between the healthcare system and its patients through digital technologies for an inclusive and open environment that allows diagnosis and treatment of stigmatized medical conditions in the comfort of patients’ homes. Prognoix’s first product, Melonga, is a self-paced digital medicine app for the management of premature ejaculation.

Privacy and data security are of utmost importance to both the patients and Prognoix. Cyberattacks may expose patients to public exposure of personal data and medical history or even financial fraud when hackers gain unlawful access to patients’ data. Through threat modeling activities and penetration testing during the development cycle provided by Irdeto, Prognoix was able to identify potential risks at an early stage, making design decisions early on to mitigate potential risks and ensure its products are highly secure. This is especially important given Prognoix’s work with healthcare systems and insurance companies to make their prescription digital medicines reimbursable.

Irdeto’s post-market cybersecurity solution is also being employed to track and manage possible vulnerabilities. especially during Prognoix’s process of entering a new and highly regulated industry. Prognoix is expanding to Germany as its beachhead market and eventually plans to expand into other European countries, the US and selected Asian markets.

Irdeto’s Connected Health portfolio offers cybersecurity solutions for medical devices’ cybersecurity needs through enterprise-grade solutions for early-stage medical devices, software as a medical device, and IoMT companies. From a cybersecurity strategy to designing security into medical devices or Software as a Medical Device (SaMD) and monitoring their vulnerabilities after their market deployment, Irdeto’s suite of proven services and solutions are architected to satisfy “state-of-the-art” medical device cybersecurity requirements.

“The partnership reinforces Irdeto’s commitment to ensuring new connected medical devices get proper cybersecurity right from the early stages of the product lifecycle. We are excited about helping Prognoix to establish itself as a strong player in the healthcare space, ensuring patient safety, system availability and protecting private health data,” said Steeve Huin, Senior Vice President & General Manager, New Markets at Irdeto.

“Premature ejaculation affects up to 30% of all men and their partners. Only a tiny fraction of those affected are currently receiving professional care, primarily due to stigma and privacy concerns. And in some countries, such as the U.S., there are no approved drugs to treat the condition. We want to change that by bringing evidence-based and trustworthy digital care within the comfort and privacy of their homes,” said Abhinav Jain, Prognoix founder and director of their European headquarters in the Netherlands.

“Irdeto has been supporting us along the entire lifecycle of our product, helping us in bringing this pioneering treatment to market,” Dr. Christoph Pies, co-founder, Prognoix, and medical officer, added. “I have seen about 1500 PE patients in the past 25 years in my urology practice. I always found myself limited by what we, as a clinician or a psychotherapist, can do to help patients and what patients really need to see long-lasting and satisfactory clinical outcomes. Melonga is meant to bridge this gap by bringing together the past three decades of clinical and behavioral research that is based on the European Association of Urology’s guidelines on the management of premature ejaculation.”

About Prognoix

Prognoix is on a mission to help stigmatized illness patients by delivering science-based clinical care within the comfort and privacy of their homes. It does so by developing low-risk digital and software medical devices that are inherently safe and follow established clinical guidelines for better clinical outcomes. Prognoix is backed by a dedicated team of engineers, clinicians, psychotherapists and medical industry experts spread all around the globe who work relentlessly for the betterment of patients and to improve access to quality medical care for all.

Please visit prognoix.com to learn more about the company and its mission.